Clinical Trials Browser

Has results × Triple Negative Breast Neoplasms × bemcentinib × Clear all

NCT03184558 2021-11-09

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Phase 2 Terminated

29 enrolled 10 charts

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms